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Introduction
Left ventricular hypertrophy (LVH), defined by an increase 
in left ventricular mass (LVM), is a common cardiac disorder 
with an estimated echocardiographic prevalence of 36–41% 
in patients with hypertension, which increases with age, hy-
pertension severity and obesity.1–3) LVH can be caused by an 
adaptation of the myocardium to increased pressure or volume 
load, genetic mutations or systemic conditions, as summarized 
in Table 1.3–16) LVH develops gradually, and therefore patients 
remain asymptomatic in early stages. When the condition pro-
gresses, symptoms related to diastolic and systolic dysfunc-
tion ultimately bring the patient to the clinic.6) Analysing the 
grade of LVH severity is of great importance to clinical practice 
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in terms of prognosis and treatment choices. An increased LVM 
is strongly linked to an increased risk of cardiovascular events.2)17) 
The three main non-invasive cardiac imaging techniques used 
to assess the severity of LVH are echocardiography, cardiac 
magnetic resonance (CMR) and computed tomography (CT).18) 
With this manuscript, we provide a comprehensive method-
ological review of different techniques for the assessment of 
symmetrical LVH based on the following parameters: wall 
thickness, LVM and left ventricle (LV) geometry. Further-
more, we provide a simplified proposal for inter-technique 
standardization. We aim to summarize LVH reference values, 
indexed by body surface area (BSA) and classified per gender 
for optimal classification of LVH severity using different imag-
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ing modalities. 
Pros and Cons of Imaging Modalities 
for Assessing LVH Severity
Echocardiography
Echocardiography was introduced in the 1950s and has be-
come the cornerstone of non-invasive imaging of the heart. 
This currently widespread technique is based on ultrasound 
waves directed to the heart, which are reflected and translated 
into several modalities that can be used to assess LVH, namely: 
M-mode echocardiography; two-dimensional echocardiogra-
phy (2DE), and three-dimensional echocardiography (3DE) 
images.19)20) The most important advantages of echocardiogra-
phy are its wide accessibility, lack of radiation exposure, and 
excellent temporal resolution, which is superior to all other 
Table 1. Overview of most important aetiologies of LVH
Summarized definition of aetiology Rationale Ref.
Obesity
BMI ≥ 30 kg/m2 A complex interplay of haemodynamic, metabolic 
and inflammatory changes have been associated  
with increased LVM 
3)4)
Hypertension
Systolic blood pressure > 140 mm Hg, or diastolic blood pressure > 90 mm Hg, 
and for patients with diabetes or chronic kidney disease: > 130 and/or  
> 80 mm Hg, respectively 
Pressure overload leads to concentric hypertrophy 5)6)
Valvular heart disease
Aortic stenosis
Defined as severe with echocardiography when valve area < 1.0 cm2, indexed 
valve area (cm2/m2 BSA) < 0.6, mean gradient > 40 mm Hg, and maximum jet  
velocity > 4.0 m/s for patients with normal cardiac output/transvalvular flow
Pressure overload leads to concentric hypertrophy 7)8)
Aortic regurgitation
Quantitatively defined as severe with echocardiography when effective 
regurgitant orifice area ≥ 30 mm2, or regurgitant volume ≥ 60 mL
Volume overload leads to eccentric hypertrophy 8)9)
Mitral regurgitation
Quantitatively defined as severe with echocardiography when the effective 
regurgitant orifice area is ≥ 40 mm2 in primary- and ≥ 20 mm2 in secondary  
mitral regurgitation, and regurgitant volume is ≥ 60 and ≥ 30 mL, 
respectively
Volume overload leads to eccentric hypertrophy 8)10)
Genetic disorders 
Hypertrophic cardiomyopathy (most prevalent)
In adults, wall thickness ≥ 15 mm in one or more LV myocardial segments–as 
measured by any imaging technique (echocardiography, CMR, or CT) that  
is not explained solely by loading conditions
Genetic mutations cause asymmetrical hypertrophy 11)
Other (genetic) disorders 
e.g., Anderson-Fabry, Pompe-, and Danon disease, cardiac amyloidosis, 
mitochondrial myopathy, mucopolysaccharidosis
More than 40 types of other (genetic) disorders can cause LVH. Diagnostic 
plasma levels of disease-specific components, genetic testing, and  
echocardiography, mostly in family members of affected persons, are some  
of the techniques used to establish the diagnosis. LVH is often discovered  
later in life than other non-cardiac manifestations
Genetic mutations cause (among others) cardiac 
anomalies like hypertrophy, valvular- and systolic  
dysfunction
12–14)
Excessive physical exercise
The definitions of ‘excessive physical exercise’ vary largely. As example we cite 
here Batterham et al.,15) who showed that training of > 10 hours per week for  
10 weeks in healthy males was associated with an absolute increase in LVM  
of 4.8%
Excessive physical exercise that requires isometric 
muscle contraction can cause concentric  
hypertrophy, while exercises that require isotonic 
muscle contraction can cause eccentric hypertrophy 
16)
LVH: left ventricular hypertrophy, BMI: body mass index, CMR: cardiac magnetic resonance, CT: computed tomography, LVM: left ventricular mass, LV: left 
ventricle 
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imaging techniques. M-mode echocardiography, often used 
for LVH assessment, has a temporal resolution up to 1 ms. 
However, echocardiography is operator and patient dependent, 
which could result in a relatively high inter-observer variabili-
ty.20–22) Furthermore, geometric assumptions represent an im-
portant limitation in LVM estimation in M-mode and 2DE, but 
this can be overcome by the use of 3DE: when 3DE measure-
ments of LVM are compared to CMR measurements as gold 
standard, they correlate better, and have smaller limits of agree-
ments, than LVM measurements with 2DE.23)24) Although over-
Table 2. Comparison of imaging modalities used for LVH severity grading
Characteristics M-mode echo 2D echo 3D echo CMR CT
Spatial resolution ++++ ++++ ++ +++ ++++
Temporal resolution ++++ +++ +++ ++ +
Radiation - - - - +
Renal failure - - - + +
Mechanical implants - - - + -
Operator dependent ++ ++ ++ + +
Low availability - - - ++ +
Cost and resources + + + +++ ++
Tissue characterization - - - +++ ++
Geometric assumptions ++ ++ - - -
LVH: left ventricular hypertrophy, echo: echocardiography, CMR: cardiac magnetic resonance, CT: computed tomography
Table 3. LV geometry and wall thickness cut-off values in guidelines and original studies for different imaging techniques
Imaging technique
LV geometry
Ref.
Ref. 
type
Normal
geometry
Concentric 
hypertrophy
Eccentric 
hypertrophy
Concentric
remodeling
LVMi RWT LVMi RWT LVMi RWT LVMi RWT
2DE (men) ≤ 115 < 0.42 > 115 > 0.42 > 115 < 0.42 ≤ 115 > 0.42 18)* GL
2DE (women) ≤ 95 < 0.42 > 95 > 0.42 > 95 < 0.42 ≤ 95 > 0.42 18)* GL
CMR (not specified 
to gender)
68 ± 11 0.38 ± 0.04 95 ± 16 0.51 ± 0.06 83 ± 10 0.38 ± 0.04 72 ± 8 0.5 ± 0.04 34)† OR
Imaging technique
Men Women
Ref.
Ref. 
typeNormal geometry LV hypertrophy Normal geometry LV hypertrophy 
CT (available for 
LVMi, in different  
classification)
< 103 ≥ 103 < 89 ≥ 89 35)‡ OR
Imaging technique
Wall thickness
Ref.
Ref. 
type
Men Women
Normal range
Mildly 
abnormal
Moderately 
abnormal
Severely
abnormal
Normal range
Mildly
abnormal
Moderately
abnormal
Severely
abnormal
Septal wall thickness: range (mm), UL or ± SD
2DE 6–10 11–13 14–16 > 16 6–9 10–12 13–15 > 15 18) GL
CMR 10.1; UL 11.7 - - - 8.9; UL 10.1 - - - 36) OR
CT 9 ± 2 - - - 8 ± 1 - - - 37) OR
Posterior wall thickness: range (mm), UL or ± SD
2DE 6–10 11–13 14–16 > 16 6–9 10–12 13–15 > 15 18) GL
CMR 9.9; UL 11.2 - - - 8.7; UL 9.8 - - - 36) OR
CT 9 ± 2 - - - 8 ± 2 - - 37) OR
*RWT = (2 × posterior wall thickness / LV internal diameter at end diastole). LVMi = [(myocardial end-diastolic volume × myocardial density) / body surface 
area], †RWT = [(inferolateral + septal wall thickness at end-diastole) / LV end-diastolic diameter]. LVMi = as guidelines. Increased RWT was defined as > 0.45 
mm, increased LVMi as > 81 g/m2 (men) or > 62 g/m2 (women), ‡LVMi: as guidelines. Criteria for abnormal LVM: above the 97th percentile for LVMi. 2DE: 
two-dimensional echocardiography, CMR: cardiac magnetic resonance, CT: computed tomography, GL: guidelines, LV: left ventricle, LVMi: left ventricle mass 
index, OR: original research, RWT: relative wall thickness (mm), SD: standard deviation, UL: upper limit, -: not available
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estimation used to be a problem in 3DE LVM measurements, 
Shimada and Shiota25) showed that accuracy of 3DE in LVM 
measurement has significantly increased over time, which was 
recently confirmed by Mizukoshi et al.,26) who showed an ex-
cellent accuracy, correlation and agreement between 3DE and 
CMR LVM measurements. 
In most patients, transthoracic echocardiography allows for 
an adequate assessment of the heart. Nevertheless, poor endo-
cardial delineation due to insufficient image quality such as in 
patients with emphysema could be solved by using either tran-
soesophageal approach or the use of contrast media.18)21)
Cardiac magnetic resonance
CMR became available in the beginning of the 1980’s27) and 
uses the nuclear magnetic resonance of hydrogen to identify 
specific tissues.28) Characteristically, it is not dependent on acous-
Fig. 1. Methodology for the measurement of the septal and posterior wall thickness, LV mass, and LV diastolic diameter with echo, CMR and CT. 
Short axis: measurements of septal and posterior wall thickness (yellow lines). 2-chamber, 4-chamber, and short axis views: contour drawing of the 
LV for three-dimensional LVM measurement (blue lines). Contour drawing may primarily be performed in short axis images (all available) and 
confirmed with long axis views; or, using primarily long axis views while rotating the LV on its longitudinal axis, and confirmed with short axis views (all 
available). LV (end-)diastolic diameter (green lines). Echo: echocardiography, CT: computed tomography, CMR: cardiac magnetic resonance, LV: left 
ventricle, LVM: left ventricular mass.
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tic windows, measurements are less operator dependent, and 
overall resolution is adequate.21)22) This technique is considered 
the gold standard for assessment of most cardiac parameters 
including LVM, also allowing for cardiac tissue characterization. 
Notwithstanding, due to its high costs and lower availability, 
it is far less utilized than echocardiography.21)22) Furthermore, 
CMR has a relatively low spatial resolution (compared with 
CT), prolonged examination time, and is relatively contraindi-
cated in patients with mechanical devices (e.g., pacemakers, 
prosthetic valves).21)22)
Computed tomography
CT utilizes X-rays that are sent through the body and ab-
sorbed at different intensities depending on the tissue. Detec-
tors on the other side of the body identify the remaining X-rays, 
which allows for tissue differentiation.29) While the first CT scan-
ners in the 1970’s had only one detector and provided conse-
quently a rather limited field of view per rotation, modern CT 
scanners have at least 64 detectors, and in the most advanced 
machines this number can reach even more than 700.29) The 
shift from electrocardiographic (ECG)-gated retrospective ac-
quisitions towards ECG-triggered prospective acquisitions for 
the purpose of radiation dose reduction, limits the availability 
of end-diastolic phases, as preferably mid-diastolic phases are 
captured.30) Until now, no data is available regarding reference 
values for parameters such as wall thickness in mid-diastole. 
Cardiac CT is predominantly used for excluding the presence 
of coronary artery disease in patients with intermediate risk.31) 
However, the use of cardiac CT is expected to expand rapidly, 
since it allows for anatomical and functional evaluation of cor-
onary lesions, and facilitates decision making before an invasive 
procedure.32)33) Furthermore, CT is used when a patient has 
contra-indications for CMR, offering an excellent spatial reso-
lution and unrestricted field of view. However, the relatively 
low temporal resolution and the radiation exposure (ranging 
from 5–20 mSv21)22)) make cardiac CT the least preferred tech-
nique among the three for LVH assessment.21) Table 2 summa-
rizes the main technically and clinically relevant characteristics 
of echocardiography, CMR and CT.
Methodology of LVH Assessment within 
Different Techniques
Guidelines with reference values for cardiac chamber quan-
tification are available for echocardiography,18) but not yet for 
CT and CMR. Consequently, the reference values provided by 
these guidelines for echocardiography are used in the clinic for 
CMR and CT. The three main parameters for the assessment 
of LVH severity are wall thickness, LVM and LV geometry.18) 
Table 3 summarizes relevant parameters with cut-off values for 
LVH severity classification from the guidelines for echocardiog-
raphy and available original reports for CMR and CT.18)34-37) 
LV thickness
According to the guidelines for chamber quantification us-
ing echocardiography,18) LV posterior wall thickness is an impor-
tant indicator for LVH severity. LV posterior wall, together 
with the LV internal diameter is used to calculate the relative 
wall thickness (RWT) as RWT = 2 × posterior wall thickness / 
LV internal diameter at end diastole. On the other hand, septal 
wall thickness gives an indication of the presence and severity 
Fig. 2. Calculation of LV mass with an echocardiographic linear method. LV: left ventricle. 
2D M-mode Calculation
Cube formula:
LV mass = 0.8 × 1.04 ×
[(SWT + LVID + PWT)3 - LVID3]
+ 0.6 g18)
Measurements of septal wall
thickness (SWT), left ventricular
internal diameter (LVID),
and posterior wall thickness (PWT), 
are performed at end-diastole.
Diameters are perpendicular to the
LV long axis, and measured at the
level of mitral valve leaflet tips. 
M-mode views are preferred, and 
obtained from targeted parasternal
short axis (upper panel) or long axis
(PLAX) views (lower panel).
Recommended for normally shaped
ventricles.
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of LVH.18) The latter parameter is often used in clinical prac-
tice.38) In echocardiography, LV thickness quantitation is per-
formed at end-diastole (the frame before mitral valve closure or 
the frame in the cardiac cycle in which the ventricular dimen-
sion or volume is the largest). Standard LV thickness measure-
ments could be performed using either M-mode or 2D linear di-
ameters.18) The posterior wall is measured in the parasternal 
long-axis or short-axis view at or immediately below the level 
of the mitral valve leaflet tips, which is approximately at the 
junction of the basal- and mid-inferolateral segments (Fig. 1). 
Likewise, both views are used for the measurement of the sep-
tal wall, corresponding to the boundary between the basal- 
and mid-anteroseptal segments (Fig. 1).18) In routine practice, 
although not formally recommended, septal thickness is often 
measured in the 4-chamber view, at the junction between the 
basal and mid inferoseptum, or simply at the level of the thick-
est portion. The appropriateness of this 2D measurement would 
require further validation. For CMR, the same reconstruction 
protocols based on 2D non-contiguous coverage of the LV or 3D 
whole-heart imaging, recreate those end-diastolic views used 
for echocardiography.39) Thus, CMR linear measurements are 
obtained from the same segments as recommended for echo-
cardiography. However, for CT, the views available for LVH as-
sessment vary according to local reconstruction protocols. In 
principal, CT multiplanar reconstructions could reproduce the 
same segmentation used for echocardiography and CMR. Cur-
rent software applications for CT- and CMR-based LV func-
tion and LVM assessment require contour delineation of the LV, 
and provide results of LV thickness using the 16-segment mod-
el, as well as LVM.40)
LVM
LVM assessment with all three techniques requires quantifi-
cation of myocardial end-diastolic volume which is calculated 
either through geometric formulas (when derived from M-mode 
or 2D images) or directly measured (in 3D imaging) (Fig. 1 and 
2). After the end-diastolic myocardial volume is calculated, it is 
converted to mass by multiplying it with the myocardial density 
(approximately 1.05 g/mL).18) To generate the LVM index 
(LVMi), the LVM is divided by BSA (resulting in the unit g/m2). 
Fig. 3. LV geometry patterns. RWT = 2 × posterior wall thickness / LV internal diameter at end diastole. LVMi = LVM / BSA. Normal = green, abnormal = 
red. Abnormal RWT is defined as > 0.42, abnormal LVMi is > 115 g/m2 (men), and > 95 g/m2 (women).18) RWT: relative wall thickness, LVMi: left 
ventricular mass index, LV: left ventricle, LVM: left ventricular mass, BSA: body surface area. 
Concentric remodeling Concentric hypertrophy
Normal geometry Eccentric hypertrophy
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Table 4. Non-invasive imaging techniques compared in assessment of wall thickness
Techniques 
compared
Results ± SD 
or range Parameter Phase Unit n
Patient 
description
CC, 
(95% CI), p
BA bias, 
LOA or SD
Calculation 
BA
Ref.
2DE vs. 3DE 2DE 3DE
28.0 ± 8.1 27.7 ± 7.5 Segm. 
WT
ED/ES mm 20 HCM r = 0.92, 
(0.90–0.94), 
p < 0.001
Bias = 0.1, 
LOA = -5.8 to 6.1
3DE - 2DE 43)
CT vs. 2DE 64-slice CT 2DE
0.9 ± 0.2 1.1 ± 0.3 Sept. 
WT
ED cm 100 Referred for 
CCTA
- Bias = 0.20, p < 0.001, 
LOA = -0.20 to 0.60
2DE - CT 37)
0.9 ± 0.2 1.0 ± 0.2 Post. 
WT
ED cm 100 Referred for 
CCTA
- Bias = 0.10, p < 0.001, 
LOA = -0.18 to 0.38
2DE - CT 37)
8.83 (range 
2.5–15.5)
11.03 (range 
7–15)
Sept. 
WT
ED mm 116 Referred for 
CCTA
r = 0.47,
p = 0.001
Bias = -24.6%, 
LOA = -76.1 to 20.9% 
CT - 2DE 44)
9.67 (range 
6–21)
9.7 (range 
7–15)
Post. 
WT
ED mm 116 Referred for 
CCTA
r = 0.243,
p = 0.104
Bias = -7.4%, 
LOA = -55.4 to 40.5% 
CT - 2DE 44)
10 ± 1.4 11 ± 1.5 Sept. 
WT
ED mm 25 Heart failure r = 0.77, 
p = 0.50
- - 45)
10 ± 1.3 10 ± 1.4 Post. 
WT
ED mm 25 Heart failure r = 0.76, 
p = 0.68
- - 45)
2DE vs. CMR 2DE CMR
10 ± 30 10 ± 10 Sept. 
WT
ED mm 44 Normal LV 
dimensions
r = 0.57,
p < 0.05
Bias = 0.6, SD = 1.9 CMR - 2DE 46)
9 ± 2 9 ± 1 Post. 
WT
ED mm 44 Normal LV 
dimensions
r = 0.49, 
p < 0.05
Bias = 0.3, SD = 1.3 CMR - 2DE 46)
28.0 ± 8.10 27.8 ± 8.00 Segm. 
WT
ED/ES mm 20 HCM r = 0.85 
(0.82–0.88),  
p < 0.001
Bias = 0.4, 
LOA = -7.7 to 8.6
CMR - 2DE 43)
21.7 ± 9.10 22.5 ± 9.60 Max LV 
WT
ED mm 48 HCM t-test, 
p = 0.21
- - 47)
13 ± 60 17± 80 BAL free 
wall
ED mm 48 HCM t-test, 
p = 0.001
- - 47)
3DE vs. CMR 3DE CMR
27.7 ± 7.50 27.8 ± 8.00 Segm. 
WT
ED/ES mm 20 HCM r = 0.90 
(0.87–0.91),
p = 0.001
Bias = 0.3,
LOA = -6.6 to 7.2
CMR - 3DE 43)
CT vs. CMR 64-slice CT CMR
- - Segm. 
WT
ED mm 80 HCM r = 0.88, 
p < 0.01
Bias = 0.61,
LOA = -5.39 to 6.61
CMR - CT 48)
21.9 ± 7.00 22.5 ± 6.60 Max 
WT
ED mm 60 HCM r = 0.96, 
p < 0.01
Bias = 0.5,
LOA = -2.4 to 3.1
CMR - CT 49)
CT vs. CMR 16-slice CT CMR
9.8 ± 3.6 10.0 ± 3.50 Segm. 
WT
ED mm 19 Various heart 
diseases
r = 0.89,
p < 0.05
Bias= -,
LOA = -3.65 to 3.15
CMR - CT 50)
13.8 ± 4.40 14.1 ± 4.30 Segm. 
WT
ES mm 19 Various heart 
diseases
r = 0.85,
p < 0.05
Bias= -,
LOA = -5.06 to 4.54
CMR - CT 50)
- - Segm. 
WT
ED mm 30 Various heart 
diseases
- Bias = -0.54, 
SD = 2.19
CMR - CT 51)
2/3DE: two/three-dimensional echocardiography, BA: Bland-Altman analysis, BAL: basal anterolateral, CC: correlation coefficient, cm: centimetre, CT: com-
puted tomography, CCTA: cardiac CT angiography, CI: confidence interval, CMR: cardiac magnetic resonance, ED: end-diastole, ES: end-systole, HCM: hyper-
trophic cardiomyopathy, LV: left ventricle, LOA: limits of agreement, Post.: posterior, r: Pearson correlation coefficient, SD: standard deviation, Segm.: segmen-
tal, Sept.: septal, WT: wall thickness, -: not available
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LV geometry
Determination of the LV geometry according to guidelines 
requires the LVMi and RWT as described above.6)18) With re-
gards to geometry, the LV can be described as normal, concentric 
remodelled, and concentric or eccentric hypertrophied, as de-
picted in Fig. 3 and Table 3. Other classifications have been sug-
gested, possibly increasing the prognostic value of LVH based 
on dilatation.41)42) As this review focuses on methodology of 
guideline based assessment of LVH severity, we would like to 
point interested readers to references on this important topic.41)42) 
Inter-Technique Agreement and 
Disagreement
Although the methods for chamber quantitation may apply 
Table 5. Non-invasive imaging techniques compared in assessment of left ventricular mass
Techniques 
compared
Results ± SD 
or range Parameter Unit n
Patient 
description
CC, 
(95% CI), p
BA bias, 
LOA or SD 
or 95% CI
Calculation 
BA
Ref.
2DE vs. 3DE 2DE 3DE
219±81 193±65 LVM g 112 Hypertension, 
aortic stenosis, 
and healthy
r = 0.85,
p < 0.001
Bias = 26 ± 42,
LOA = -58 
to + 110
M-mode -
3DE
52)
CT vs. 2DE 64-Slice CT 2DE
119 ± 30 115 ± 38 LVM g 100 Referred for 
CCTA
- Bias = -4, 
t-test 
p = n.s.
2DE - CT 37)
95.73 205.5 LVM g 116 Referred for 
CCTA
r = 0.419, 
p = 0.006
Bias = -7.09, 
LOA = -151.5 
to 9.6%
CT - 2DE 44)
Echo vs. CMR 2DE CMR
178.2 ± 46.0 171.0 ± 52.4 LVM g 35 LVH r = 0.989 Bias = 7.20, 
LOA = -37 to 
50
CMR - 2DE 53)
194.4 ± 52.9 0.107 ± 24.4 LVMi g/m2 67 Heart failure 
and low EF
r = 0.45 
(0.18–0.65),
p = 0.002
Bias = -79.9, 
LOA = -173.4 
to 13.5
CMR - 2DE 54)
- 177 ± 56 LVM g 25 Healthy and 
various heart 
conditions
r = 0.91 Bias = 15.9 ± 
95% CI 54.9
CMR - 2DE 55)
Echo vs. CMR 3DE CMR
248 ± 93 248 ± 93 LVM g 20 HCM r = 0.97,
p < 0.001
Bias = -6.3,
LOA = 
-54.7 to 42.2
CMR - 3DE 43)
- 177 ± 56 LVM g 25 Healthy and 
various heart 
conditions
r = 0.99 Bias = 1.2 ± 95% 
CI 12.7
CMR - 3DE 55)
CT vs. CMR 64-Slice CT CMR
022.6 ± 12.7 
(range, 7.3–45.0)
024.2 ± 13.0 
(range, 9.3–47.1)
MDE mass g 80 HCM r = 0.97, 
p < 0.01
Bias = -1.26, 
LOA = 
-7.80–4.55
CMR - CT 48)
136.2 ± 51.9 152.5 ± 57.8 LVM g 36 Referred for 
CCTA
r = 0.93,
p > 0.001
LOA = ± 42.0 CMR - CT 56)
207.5 ± 88.1 210.6 ± 83.6 LVM g 60 HCM r = 0.95, 
p < 0.01
Bias = 3.1, 
LOA = -50.1 
to 56.3
CMR - CT 49)
2/3DE: two/three-dimensional echocardiography, BA: Bland-Altman analysis, CC: correlation coefficient, CT: computed tomography, CCTA: cardiac CT angi-
ography, CI: confidence interval, CMR: cardiac magnetic resonance, HCM: hypertrophic cardiomyopathy, LOA: limits of agreement, LV: left ventricle, LVH: 
LV hypertrophy, LVM: left ventricular mass, LVMi: left ventricular index, MDE: myocardial delayed enhancement, r: Pearson correlation coefficient, SD: stan-
dard deviation, -: not available, EF: ejection fraction
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for all techniques, differences in spatial and temporal resolu-
tion can account for variations in reference values, as shown by 
comparative studies,37)43-56) of which the most important results 
are summarized in Table 4 and 5 for wall thickness and LVM, 
respectively. The comparative studies show that agreement is 
acceptable between techniques. When echocardiography is com-
pared to CMR or CT in the measurement of wall thickness 
and LVM, generally a weaker Pearson’s correlation and a larger 
bias with accompanying limits of agreement are found37)43-47)53-55) 
than when CMR and CT are compared,48-51)56) indicating that 
the most important drawback of echocardiography is the larg-
er operator dependence, as compared to CMR and CT; most 
likely caused by the lower spatial resolution of echocardiogra-
phy. Noteworthy, a difference of 2 mm in septal wall thickness 
could reclassify the presence and/or the severity of LVH (Table 
3).6)18) Interestingly, although CMR is considered the gold 
standard for measurement of most cardiac parameters, CT is 
known to be the least operator dependent when it comes to 
measurements of for example the aorta and aortic annulus.57)58) 
The studies cited in Table 4 and 5, however, do not show a clear 
difference in operator dependence when CMR and CT are 
compared, indicating that for the parameters that are used for 
LVH severity assessment, both CMR and CT will suffice if the 
quality of echocardiographic measurements of parameters that 
are relevant for LVH severity assessment are not sufficient. 
Gender, Ethnicity, Age, and Body 
Surface Area
Several studies have shown that gender, age, body size, and 
ethnicity influence reference values for cardiac parameters.2)18) 
Accordingly, reference values should be examined with caution. 
Indexing the LVM to BSA or heightx (where x stands for allo-
metric powers such as 1.7, 2.13, or 2.7) allows for better com-
parison of persons with different body sizes. However, the op-
timal indexing method remains controversial. Most studies 
have used LVM/BSA, nevertheless recent data suggests that 
indexing LVM to heightx may more accurately predict events 
in obese patients.18) Paucity of data in this regard prompts the 
need for continued research in populations with normal and 
hypertrophied hearts. 
Conclusion
LVH severity grading is important for diagnosis, prognosis 
and guidance of therapy. Three main parameters including 
wall thickness, left ventricular mass, and left ventricular geom-
etry, are easily assessed with echocardiography, CT or CMR. 
Data representing normal populations is abundant for echo-
cardiography, however still limited for CT or CMR. A standard 
methodology for LVH severity grading among modalities is 
advised to further improve comparability and facilitate clinical 
decision making. 
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